Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affitech AS
Affitech Appoints Sergej Kiprijanov New Head of Research
March 2nd, 2008
The human antibody company, Affitech AS, announced the appointment of Dr. Sergej Kiprijanov as the Vice President of Discovery Research and Preclinical Development. Joining Affitech at a key stage in the company's growth, Dr. Kiprijanov brings a wealth of experience in the antibody therapeutic field. Previously CSO of Novoplant GmbH, a German plant biotech company developing antibodies for oral applications, Dr. Kiprijanov was also Head of Research with Affimed Therapeutics AG in Heidelberg, Germany, focusing on engineering human antibodies and antibody fragments for cancer indications. Welcoming the appointment, Affitech CEO Dr. Martin Welschof said, "Dr. Kiprijanov...
Source: Pharma Investments, Ventures & Law Weekly (2008-03-02)
|
